Sana Biotechnology (NASDAQ:SANA) Stock Rating Upgraded by Citizens Jmp

Sana Biotechnology (NASDAQ:SANA – Get Free Report) was upgraded by research analysts at Citizens Jmp from a “market perform” rating to an “outperform” rating in a research note issued to investors on Tuesday, Marketbeat reports. The firm currently has a $5.00 target price on the stock. Citizens Jmp’s price objective indicates a potential upside of […]

Leave a Reply

Your email address will not be published.

Previous post AVITA Medical (NASDAQ:RCEL) Given Buy Rating at D. Boral Capital
Next post Incyte (NASDAQ:INCY) Lowered to “Market Perform” Rating by William Blair